This volume introduces in a coherent and comprehensive fashion the Pan Stanford Series on Nanobiobiotechnology by defining and reviewing the major sectors of Nanobiotechnology and Nanobiosciences with respect to the most recent developments. Nanobiotechnology indeed appears capable of yielding a scientific and industrial revolution along the routes correctly foreseen by the numerous programs on Nanotechnology launched over the last decade by numerous Councils and Governments worldwide, beginning in the late 1995 by the Science and Technology Council in Italy and by the President Clinton in USA and ending this year with President Putin in Russian Federation.
Bioinformatics and Fluorescence DNASER for NAPPA Studies on Cell Transformation and Cell Cycle, V Sivozhelezov et al.
Label Free Detection of Nappa via Mass Spectrometry, R Spera et al.
Label-Free NAPPA: Anodic Porous Alumina, E Stura et al.
Label Free Detection of NAPPA via Atomic Force Microscopy, M Sartore et al.
Cell Free Expression and APA for NAPPA and Protein Nanocrystallography, E Pechkova et al.
Structural and Functional Studies on the Helicobacter Pylori Proteome: The State of the Art, G Zanotti & L Cendron
Overall Proteome Alterations During Reverse Transformation of Growing Cho-K1 Cells, R Spera et al.
Organ Transplants and Gene Microarrays, R Danger et al.
Signaling Networks, Simulations of Biochemical Interactions. Applications to Molecular Oncology, L Tortolina et al.
Label-Free Detection of NAPPA: Surface Plasmon Resonance, M Fuentes et al.
Dr. Joshua LaBaer is one of the nation’s foremost investigators in the rapidly expanding field of personalized medicine. Formerly director of the Harvard Institute of Proteomics (HIP), he was recently recruited to ASU’s Biodesign Institute as the first Piper Chair in Personalized Medicine.
Dr. LaBaer’s efforts involve leveraging the Center’s formidable resources for the discovery and validation of biomarkers—unique molecular fingerprints of disease—which can provide early warning for those at risk of major illnesses, including cancer and diabetes. This work is carried out in conjunction with the Partnership for Personalized Medicine, a multi-institution effort that includes the Translational Genomics Research Institute (TGen) in Phoenix and the Fred Hutchinson Cancer Research Institute in Seattle.
Dr. LaBaer completed his internship and residency at the Brigham and Women’s Hospital and a clinical fellowship in Oncology at the Dana-Farber Cancer Institute, both in Boston. He is a board certified physician in Internal Medicine and Medical Oncology and was an Instructor and Clinical Fellow in Medicine at Harvard Medical School. He has contributed more than 60 original research publications, reviews and chapters. Dr. LaBaer is an associate editor of the Journal of Proteome Research, Analytical Biochemistry, and a member of the Scientific Advisory Boards for the Proteome Society, Promega Corporation, Lumera-Plexera Corporation, Barnett Institute, and a founding member of the Human Proteome Organization.
"Functional Proteomics and Nanotechnology provides valuable insight into a new dimension of concepts and approaches that will enhance capabilities to establish signatures of gene expression for biological control and pathologies."
—Prof. Gary Stein, University of Massachussetts, USA